title: Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease.
abstract: Increasing evidence links Alzheimer's disease (AD) with misbalanced Cu homeostasis. Recently, we have shown that dietary Cu supplementation in a transgenic mouse model for AD increases bioavailable brain Cu levels, restores Cu, Zn-super oxide-1 activity, prevents premature death, and lowers A beta levels. In the present report we investigated AD patients with normal levels of A beta 42, Tau and Phospho-Tau in the cerebrospinal fluid (CSF) in comparison with AD patients exhibiting aberrant levels in these CSF biomarkers. The influence of these cerebrospinal fluid (CSF) diagnostic markers with primary dependent variables blood Cu, Zn and ceruloplasmin (CB) and secondary with CSF profiles of Cu, Zn and neurotransmitters was determined. Multivariate tests revealed a significant effect of factor diagnostic group (no AD diagnosis in CSF or AD diagnosis in CSF) for variables plasma Cu and CB (F=4.80; df=2, 23; p=0.018). Subsequent univariate tests revealed significantly reduced plasma Cu (-12.7%; F=7.05; df=1, 25; p=0.014) and CB (-14.1%; F=9.44; df=1, 24; p=0.005) levels in patients with aberrant CSF biomarker concentrations. Although only AD patients were included, the reduced plasma Cu and CB levels in patients with a CSF diagnosis of advanced AD supports previous observations that a mild Cu deficiency might contribute to AD progression.
authors.affiliation: Department of Psychiatry and Psychotherapy, Saarland University, Homburg/Saar, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Kessler
authors.forename: F-G
authors.initials: FG
authors.lastname: Pajonk
authors.forename: P
authors.initials: P
authors.lastname: Meisser
authors.forename: T
authors.initials: T
authors.lastname: Schneider-Axmann
authors.forename: K-H
authors.initials: KH
authors.lastname: Hoffmann
authors.forename: T
authors.initials: T
authors.lastname: Supprian
authors.forename: W
authors.initials: W
authors.lastname: Herrmann
authors.forename: R
authors.initials: R
authors.lastname: Obeid
authors.forename: G
authors.initials: G
authors.lastname: Multhaup
authors.forename: P
authors.initials: P
authors.lastname: Falkai
authors.forename: T A
authors.initials: TA
authors.lastname: Bayer
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000097:blood / Q000134:cerebrospinal fluid*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002570:Ceruloplasmin / Q000134:cerebrospinal fluid*; D002851:Chromatography, High Pressure Liquid; D003300:Copper / Q000097:blood* / Q000134:cerebrospinal fluid; D005260:Female; D006801:Humans; D008297:Male; D018377:Neurotransmitter Agents / Q000134:cerebrospinal fluid; D013054:Spectrophotometry, Atomic; D015032:Zinc / Q000097:blood; D016875:tau Proteins / Q000134:cerebrospinal fluid*
chemical_list: D016229:Amyloid beta-Peptides; D015415:Biomarkers; D018377:Neurotransmitter Agents; D016875:tau Proteins; D003300:Copper; D002570:Ceruloplasmin; D015032:Zinc